Down 35%! This Just Shouldn't Happen

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

How does something like this happen?

Drugmakers talk to the Food and Drug Administration regularly about the design of their clinical trials. Roche has a ton of experience bringing new drugs to market. And yet, the drugmaker received a "refuse to file" letter from the FDA.

Having the FDA refuse to accept an application is about the worst thing that can happen to a drugmaker. It means the agency gave the application a onceover and decided it wasn't even worthy of a review. Drugmakers sometimes get sent back to the drawing board because of missing paperwork, but in this case the FDA refused to look at the application for Roche's trastuzumab-DM1 (T-DM1) because the agency says Roche didn't test the cancer drug in the right population of patients. Roche was seeking an accelerated approval, which requires less data, but can only be used for patients who don't have any other options; the FDA didn't think that was the case for the patients who went through Roche's phase 2 trial.

I don't know where the communication broke down. Did the FDA just spring this on Roche, or has the agency been saying this all along, and Roche just refused to listen to the advice? Either way, it shouldn't have happened.

The big loser in all this is Roche's partner, ImmunoGen (Nasdaq: IMGN  ) , which plummeted 35% today. The company developed the DM1 part of the T-DM1 and was set to get royalty and milestone payments after the approval. Instead it'll have to wait until the phase 3 trial testing T-DM1 against a combination of Roche's Xeloda and GlaxoSmithKline's (NYSE: GSK  ) Tykerb, which should be available in time for a mid-2012 filing.

While the delay in getting paid is disappointing, it's not disastrous for ImmunoGen. There's no reason to think the drug doesn't work, and the phase 3 trial needed to be completed in order for the drug to stay on the market after an accelerated approval anyway. Patient investors willing to wait for T-DM1 and for ImmunoGen's partnerships with sanofi-aventis (NYSE: SNY  ) , Biogen Idec (Nasdaq: BIIB  ) , and Biotest to pan out can grab ImmunoGen at discounted prices.

Run on over and check out Tim Hanson's pitch for Adidas.

GlaxoSmithKline is a Motley Fool Global Gains selection. Investing internationally doesn't have to be scary and it can certainly be profitable. Click here to grab a 30-day trial subscription to the newsletter where you'll see all of our current picks for a global economy.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of Glaxo and has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (9)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1283630, ~/Articles/ArticleHandler.aspx, 9/27/2016 3:06:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,214.88 120.05 0.66%
S&P 500 2,158.54 12.44 0.58%
NASD 5,300.78 43.29 0.82%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 2:49 PM
BIIB $313.68 Up +3.86 +1.25%
Biogen CAPS Rating: *****
GSK $43.30 Up +0.34 +0.79%
GlaxoSmithKline CAPS Rating: ***
IMGN $2.75 Down -0.02 -0.72%
ImmunoGen CAPS Rating: ****
SNY $38.19 Up +0.15 +0.39%
Sanofi CAPS Rating: *****